A high expression of β2 integrins has been correlated with progressive disease [166]; however, in a cohort of 113 CLL patients, low expression levels of CD18 were correlated with advanced disease (Rai stage III–IV) and a diffuse BM pattern [167]. Here, ITGB2 is linked to B-cell chronic lymphocytic leukemia.